Abbott reported second-quarter 2026 sales of $12.593 billion, up 13.0% from a year earlier, with comparable sales rising 4.8%.
Diluted earnings per share were $0.53 on a GAAP basis and $1.31 adjusted. Abbott raised its full-year 2026 adjusted EPS guidance to $5.45 to $5.60, up from $5.38 to $5.58 previously, while keeping comparable sales growth guidance at 6.5% to 7.5%.
The company returned $2.1 billion to shareholders in the quarter through dividends and share repurchases.
By division, medical devices was Abbott’s largest business in the quarter, with sales of $5.853 billion, up 9.0% reported and 8.4% comparable. Electrophysiology led the segment with sales of $861 million, up 14.0% reported and 13.4% comparable. Rhythm management rose 10.4% reported to $743 million, diabetes care increased 10.5% to $2.188 billion, and heart failure grew 6.1% to $803 million. Structural heart sales were $597 million, up 2.7% reported and 5.1% comparable.
Diagnostics sales jumped to $3.092 billion from $2.174 billion a year earlier, a 42.3% reported increase and 2.9% comparable growth. Core laboratory diagnostics rose 4.4% to $1.418 billion. Cancer diagnostics reached $919 million, with comparable growth of 13.3%. Rapid and molecular diagnostics fell 7.3% reported to $755 million.
Nutrition sales declined 3.1% to $2.144 billion, with comparable sales down 3.6%. U.S. nutrition sales fell 9.0% to $871 million, while international nutrition sales rose 1.4% to $1.273 billion.
Established pharmaceuticals sales increased 8.4% to $1.499 billion, with comparable growth of 8.7%. Key emerging markets rose 9.8% to $1.164 billion.
For the first half, Abbott reported sales of $23.757 billion, up 10.5% reported and 4.3% comparable. Medical devices first-half sales were $11.392 billion, diagnostics $5.272 billion, nutrition $4.161 billion, and established pharmaceuticals $2.925 billion.
Abbott also said it completed enrollment in its Tectonic U.S. pivotal trial in April, presented new late-breaking data from four clinical trials at the Heart Rhythm Society conference, secured CE Mark for Libre Duo in May, completed its FDA submission for Amulet 360 in May, and noted updated colorectal cancer screening guidelines that reaffirmed Cologuard and Cologuard Plus. The market has reacted to these announcements by moving the company's shares 12.5% to a price of $100.425. For the full picture, make sure to review ABBOTT LABORATORIES's 8-K report.
